. . . . . . . . . . . . . . . "Approximately 75%"@en . . . . . "Proguanilum"@en . "Take with food."@en . . . "Plasmodium"@en . . "Chloroguanide"@en . "Chlorguanide"@en . "Proguanil"@en . . "For the causal prevention and suppression of malaria caused by susceptible strains of P. falciparum and other species of Plasmodium found in some geographical areas of the world."@en . "approved"@en . "500-92-5"@en . . . "N-(4-Chlorophenyl)-n'-(isopropyl)-imidodicarbonimidic diamide"@en . . . . "Approximately 20 hours"@en . . "Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, Plasmodium falciparum and Plasmodium vivax, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite."@en . . . . "Dhananjay Govind Sathe, Harish Kashinath Mondkar, Tanaji Shamrao Jadhav, Nitin Nivrutti Hagavane, \"Process of Preparation of Proguanil.\" U.S. Patent US20110263901, issued October 27, 2011."@en . . . "Proguanil inhibits the dihydrofolate reductase of plasmodia and thereby blocks the biosynthesis of purines and pyrimidines, which are essential for DNA synthesis and cell multiplication. This leads to failure of nuclear division at the time of schizont formation in erythrocytes and liver."@en . . . . . . "Rapidly and well absorbed in humans following oral doses ranging from 50 to 500 mg."@en . "1-(P-Chlorophenyl)-5-isopropylbiguanide"@en . . . . " N-(4-Chlorophenyl)-n'-(isopropyl)-imidodicarbonimidic diamide"@en . . . .